Dr. Hong-Ren Wang
President & Chief Executive Officer
Dr. Hong-Ren Wang received his Ph.D degree in Materials Science and Engineering from Massachusetts Institute of Technology in Cambridge, Massachusetts, M.S. degree in Materials Science and Engineering from National Tsing Hua University in Taiwan, and B.S degree in Chemical Engineering from National Taiwan University in Taiwan. Prior joining PharmaEngine, he had worked with Transform Pharmaceuticals (a subsidiary company of Johnson & Johnson, Lexington Massachusetts), Vertex Pharmaceuticals (Boston, Massachusetts), Microchips Biotech (Lexington, Massachusetts), and Proteostasis Therapeutics (Boston, Massachusetts) with increasing responsibilities in drug development. His broad industry experience includes selection and development of new chemical entities (NCEs) from preclinical to NDA/MAA applications including three FDA/EMA approved commercial products. He also worked on novel drug delivery/device combination through drug evaluation, PK/device combination modeling, and novel formulation design. He recently served as Vice President of Product Development at Proteostasis Therapeutics leading efforts in developing a triple drug combination therapy.
Vice President, Corporate Development
Mr. Chang joined PharmaEngine in February 2003. He is a certified public accountant (CPA) in Taiwan. He worked at TTY Biopharm as the Director of Stock Affairs Department, and MasterLink Securities and Sampo Securities for many years majored in IPOs in Taiwan. He received his Master degree of Accounting from National Taiwan University, Taipei, Taiwan.
Senior Director, Marketing & Sales
Mr. Wu joined PharmaEngine in July 2004. He majored in marketing and sales of oncology products at Novartis (Taiwan) and Kirin (Taiwan), responsible for Glivec®, Aredia®, G-CSF and EPO. Mr. Wu received his Bachelor degree in Pharmacy, Taipei Medical University, Taipei, Taiwan